Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Nephrology, Dialysis and Transplantation

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/NDT/11.1.165PMID 8649628
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic interaction between cyclosporin and diltiazem

  2004cited by this paper
• Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing

  2004cited by this paper
• Long-term efficacy and safety of cyclosporine in renal-transplant recipients.

  1994cited by this paper
• Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients

  1994cited by this paper
• CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS

  1994cited by this paper
• Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month.

  1994cited by this paper
• Cyclosporine Neoral in liver transplant recipients.

  1994cited by this paper
• Oral microemulsion formulation substitutes for intravenous cyclosporin in child with graft-versus-host disease.

  1994cited by this paper
• Cyclosporin Clinical Pharmacokinetics

  1993cited by this paper
• Cyclosporin absorption from microemulsion formulation in liver transplant recipient.

  1993cited by this paper
• Risk factors for chronic rejection in renal allograft recipients.

  1993cited by this paper
• Twenty-five years of renal transplantation from a single center: a risk factor analysis for short- and long-term outcomes

  1993cited by this paper
• A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

  1990cited by this paper
• Covariables in cyclosporine immunosuppression.

  1990cited by this paper
• Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels.

  1990cited by this paper
• Effect of Food on the Pharmacokinetics of Cyclosporine in Healthy Subjects Following Oral and Intravenous Administration

  1990cited by this paper
• Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways.

  1990cited by this paper
• Pharmacokinetic Drug Interactions with Cyclosporin (Part II)

  1990cited by this paper
• Cyclosporine.

  1989cited by this paper
• Interaction of cyclosporin and calcium antagonists.

  1989cited by this paper
• The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients.

  1988cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Side Effects of Transplant Immunosuppressive Therapy in Post Renal Transplant Recipients, Mazandaran, Northern Iran

  2017cites this paper
• CyclosporinReview of the Pharmacokinetic Properties, Clinical Efficacy and Tolerability of a Microemulsion-Based Formulation (Neoral ® ) 1 in Organ Transplantation

  2016cites this paper
• Immunosuppression and Results in Renal Transplantation

  2016cites this paper
• Influencing Factors of New-Onset Diabetes after a Renal Transplant and Their Effects on Complications and Survival Rate

  2014cites this paper
• Cyclosporin

  2012cites this paper
• Is short term outcome of Iranian renal transplant recipients affected by mean first 6 months C2 level?

  2009cites this paper
• Therapeutic equivalence and mg:mg switch ability of a generic cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients maintained on Sandimmun Neoral.

  2008cites this paper
• Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal.

  2007cites this paper
• Coronary artery disease and nuclear imaging in renal failure

  2006cites this paper
• [Cyclosporine dose monitorization in renal transplantation C2 vs C0].

  2005cites this paper
• Therapeutic drug monitoring of cyclosporine.

  2004cites this paper
• The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression.

  2004cites this paper
• Cyclosporin C2hour monitoring after renal transplantation.

  2003cites this paper
• Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.

  2001cites this paper
• Risk factors of cyclosporine nephrotoxicity after conversion from Sandimmune to Neoral.

  2001cites this paper
• New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.

  2001cites this paper
• Calcineurin inhibitors and chronic renal allograft dysfunction: Not enough or too much?

  2001cites this paper
• Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral Sandimmune to Neoral.

  1999cites this paper
• Conversion from sandimmune to neoral in renal allograft recipients

  1999cites this paper
• Overview of the clinical experience with Neoral in transplantation.

  1999cites this paper
• Converting renal transplant patients maintained on Sandimmune to a new microemulsion formulation, Sandimmune Neoral.

  1998cites this paper
• Acute illness superimposed on chronic renal failure

  1998cites this paper
• RANDOMIZED, DOUBLE-BLIND, ONE-YEAR STUDY OF THE SAFETY AND TOLERABILITY OF CYCLOSPORINE MICROEMULSION COMPARED WITH CONVENTIONAL CYCLOSPORINE IN RENAL TRANSPLANT PATIENTS

  1998cites this paper
• Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.

  1998cites this paper
• The nephrotoxicity of new and old immunosuppressive drugs.

  1998cites this paper
• Simple bioequivalence criteria: are they relevant to critical dose drugs? Experience gained from cyclosporine.

  1997cites this paper
• Cyclosporine‐induced hypertension and decline in renal function in healthy volunteers

  1997cites this paper